Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Myelodysplastic syndrome

Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. 3.

    Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. 4.

    Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. 5.

    Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010;24:1656–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. 6.

    Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118:6920–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. 7.

    Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29:2499–506.

    Article  PubMed  CAS  Google Scholar 

  8. 8.

    Yannakou CK, Jones K, McBean M, Thompson ER, Ryland GL, Doig K, et al. ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach. Blood Cancer J. 2017;7:656.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, et al. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2017;31:872–81.

    Article  PubMed  CAS  Google Scholar 

  10. 10.

    Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.

    Article  PubMed  CAS  Google Scholar 

  11. 11.

    Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119:3578–84.

    Article  PubMed  CAS  Google Scholar 

  12. 12.

    Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. 13.

    Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. 14.

    Carter JH, McNulty SN, Cimino PJ, Cottrell CE, Heusel JW, Vigh-Conrad KA, et al. Targeted next-generation sequencing in molecular subtyping of lower-grade diffuse gliomas: application of the World Health Organization’s 2016 revised criteria for central nervous system tumors. J Mol Diagn. 2017;19:328–37.

    Article  PubMed  CAS  Google Scholar 

  15. 15.

    Feng W, Zhao S, Xue D, Song F, Li Z, Chen D, et al. Improving alignment accuracy on homopolymer regions for semiconductor-based sequencing technologies. BMC Genom. 2016;17:521.

    Article  Google Scholar 

Download references

Acknowledgements

We thank David Spencer, Chad Storer, and Catherine Cottrell for helpful discussions; and Felicitas Thol, Torsten Haferlach, Elli Papaemmanuil, Olivier Kosmider, and R. Coleman Lindsley for discussions and data related to their publications. Support was provided to MJW through a SPORE in Leukemia grant (P50CA171963) from the National Institutes of Health/National Cancer Institute (NIH/NCI), the Edward P. Evans Foundation, the Lottie Caroline Hardy Trust, and a Leukemia and Lymphoma Society Scholar Award. Support for procurement of human samples was provided by an NIH/NCI grant (P01CA101937). Technical assistance was provided by the Alvin J. Siteman Cancer Center Tissue Procurement Core supported by an NCI Cancer Center Support Grant (P30CA91842).

Author information

Affiliations

Authors

Contributions

Conception and design: MOA, EJD, MJW; methodology: MOA, SNS, EJD, CAM, QG, LD, MJW; data acquisition and analysis: MOA, SNS, JS, SNM, GSC, JBD, FY, RDP; interpretation of data: MOA, SNS, MJW; writing: MOA and MJW with all authors contributing to and approving the final manuscript; project supervision: JWH, EJD, MJW.

Corresponding author

Correspondence to Matthew J. Walter.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alberti, M.O., Srivatsan, S.N., Shao, J. et al. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia 32, 1874–1878 (2018). https://doi.org/10.1038/s41375-018-0193-y

Download citation

Further reading

Search

Quick links